title: Targeted Chemotherapy with Metal Complexes.
abstract: Classical chemotherapeutics, such as cisplatin and its analogues, have been highly successful in the clinic, yet improvements can certainly be made, given the significant side effects associated with the killing of healthy cells. Recent advances in the field of chemotherapy include the development of targeted anticancer agents, compounds that are directed towards a specific biomarker of cancer, with the hopes that such targeted therapies might have reduced side effects given their greater selectivity. Here we discuss several transition metal complexes that are tailored towards various biomolecules associated with cancer. Most notably, the success of rhodium metalloinsertors, which specifically bind to nucleic acid base mismatches in DNA, highlight the enormous potential of this exciting new strategy.
authors: Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125.
authors: Alyson G
authors: AG
authors: Weidmann
authors: Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125.
authors: Alexis C
authors: AC
authors: Komor
authors: Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125.
authors: Jacqueline K
authors: JK
authors: Barton
keywords: DNA mismatch repair; bioinorganic; medicinal chemistry
references: J Med Chem. 2008 Nov 13;51(21):6773-81
references: 18834187
references: Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):429-34
references: 17194756
references: J Am Chem Soc. 2012 Nov 21;134(46):19223-33
references: 23137296
references: Dalton Trans. 2006 Jan 28;(4):529-41
references: 16402138
references: Chem Biol. 2013 Nov 21;20(11):1323-8
references: 24183971
references: Biochemistry. 1999 Apr 13;38(15):4655-62
references: 10200152
references: Nat Chem. 2012 Jun 10;4(8):615-20
references: 22824892
references: J Inorg Biochem. 2013 Jan;118:94-9
references: 23142974
references: J Proteomics. 2012 Dec 21;77:492-503
references: 23041048
references: Angew Chem Int Ed Engl. 2010 Jul 19;49(31):5226-7
references: 20589820
references: J Clin Invest. 1996 Jul 1;98(1):199-206
references: 8690794
references: Clin Chim Acta. 2000 Feb 15;291(2):113-35
references: 10675719
references: Biochemistry. 2000 May 23;39(20):6176-82
references: 10821692
references: Nat Genet. 2007 May;39(5):655-60
references: 17417639
references: J Med Chem. 2005 Apr 21;48(8):2814-21
references: 15828819
references: J Inorg Biochem. 1999 Oct;77(1-2):111-5
references: 10626362
references: PLoS One. 2013 Oct 29;8(10):e78726
references: 24205301
references: Trends Cell Biol. 2008 Apr;18(4):165-73
references: 18296052
references: Dalton Trans. 2010 Sep 21;39(35):8113-27
references: 20593091
references: Philos Trans A Math Phys Eng Sci. 2013 Jun 17;371(1995):20120117
references: 23776288
references: Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6319-23
references: 8022779
references: J Am Chem Soc. 2011 Apr 20;133(15):5976-86
references: 21446733
references: J Am Chem Soc. 2009 Feb 18;131(6):2359-66
references: 19175313
references: Biochemistry. 2011 Dec 20;50(50):10919-28
references: 22103240
references: Cancer Res. 1994 Aug 15;54(16):4308-12
references: 8044777
references: Cancer Res. 2001 Apr 15;61(8):3230-9
references: 11309271
references: J Am Chem Soc. 2007 Oct 10;129(40):12287-95
references: 17877349
references: Nat Rev Drug Discov. 2005 Apr;4(4):307-20
references: 15789122
references: Chem Rev. 1999 Sep 8;99(9):2467-98
references: 11749487
references: Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15359-63
references: 17030786
references: Biochemistry. 2009 May 26;48(20):4247-53
references: 19374348
references: Cancer Treat Rev. 2004 Feb;30(1):53-81
references: 14766126
references: Chem Commun (Camb). 2009 Mar 7;(9):1001-10
references: 19225621
references: Chem Rev. 2006 Feb;106(2):302-23
references: 16464007
references: Nature. 1969 Apr 26;222(5191):385-6
references: 5782119